Alessandro Pontoglio

Department of Chemistry, Materials and Chemical Engineering "Giulio Natta", Politecnico di Milano, Piazza Leonardo da Vinci 32, 20133 Milano, Italy.

16 publications 2004 – 2023

What does Alessandro Pontoglio research?

Alessandro Pontoglio studies the impact of the multikinase inhibitor Sorafenib on cancer cells, particularly liver cancer. His research investigates how this drug interacts with cancer cell metabolism, specifically how it affects glycolysis, which is the process of breaking down glucose for energy. By understanding these interactions, Pontoglio seeks ways to enhance the drug's effectiveness in killing cancer cells, especially in cases where patients show resistance to treatment.

Key findings

  • Sorafenib alone had limited effectiveness in killing liver cancer cells, highlighting its challenges as a stand-alone treatment.
  • When glucose was withdrawn, Sorafenib's effectiveness in killing liver cancer cells increased significantly.
  • The use of glycolysis blockers alongside Sorafenib led to a marked enhancement in cancer cell death, indicating a potential combined treatment strategy.

Frequently asked questions

Does Dr. Pontoglio study liver cancer?
Yes, Dr. Pontoglio focuses specifically on liver cancer and the effects of Sorafenib on cancer cells.
What does Dr. Pontoglio’s research suggest about Sorafenib?
His research indicates that Sorafenib can be more effective in killing liver cancer cells when glucose is limited or when combined with glycolysis blockers.
Is Dr. Pontoglio's work relevant for cancer patients?
Yes, his findings can help develop more effective treatment options for cancer patients, particularly those with liver cancer.

Publications in plain English

Study of Innovative GO/PBI Composites as Possible Proton Conducting Membranes for Electrochemical Devices.

2023

Membranes

Di Virgilio M, Basso Peressut A, Pontoglio A, Latorrata S, Dotelli G

Plain English
This study looked at new types of membranes made from a mix of two materials, polybenzimidazole (PBI) and graphene oxide (GO), to improve their use in devices that conduct protons, which are essential in energy applications. Researchers created membranes with different ratios of GO and PBI and found that one specific combination (GO/PBI 2:1) had a proton conductivity of 0.0464 S/cm at 100°C, performing as well as or better than existing materials. This research is important because it shows a way to create more effective membranes that could lead to better energy devices. Who this helps: This benefits engineers and scientists working on energy technologies and advanced materials.

PubMed

Mitochondrial Respiratory Complexes as Targets of Drugs: The PPAR Agonist Example.

2022

Cells

Bottoni P, Pontoglio A, Scarà S, Pieroni L, Urbani A +1 more

Plain English
This research studied how certain drugs, called PPAR ligands, affect the energy production in mitochondria, which are the powerhouses of our cells. The findings revealed that these drugs caused more extensive damage to mitochondrial function than just disrupting one part of the energy-making process. Specifically, they led to a significant drop in the ability of mitochondria to produce energy and increased stress on the cells, indicating potential harm to overall cell health. Who this helps: This helps patients taking PPAR drugs, as well as doctors who prescribe these medications.

PubMed

Functional analysis of six uncharacterised mutations in LDLR gene.

2019

Atherosclerosis

Gomez A, Colombo R, Pontoglio A, Helman L, Kaeser L +4 more

Plain English
This study focused on understanding how six specific mutations in the LDLR gene, which is linked to a condition called familial hypercholesterolemia (FH), affect the function of the low-density lipoprotein receptor. The researchers found that these mutations impact receptor activity differently, with some having near-normal activity and others functioning at less than 10% of normal levels. This is important because it helps clarify which mutations can lead to higher cholesterol levels in patients and improve genetic testing and diagnosis for FH. Who this helps: This helps patients, especially those with familial hypercholesterolemia, as well as doctors in determining the best course of action for treatment.

PubMed

Mild orotic aciduria in UMPS heterozygotes: a metabolic finding without clinical consequences.

2017

Journal of inherited metabolic disease

Wortmann SB, Chen MA, Colombo R, Pontoglio A, Alhaddad B +16 more

Plain English
This study looked at 11 people with mild elevations of orotic acid in their urine, which is usually linked to serious health issues but not in these cases. Researchers found that all these individuals had mutations in a gene called UMPS, but none showed significant health problems like anemia or abnormal blood counts. This is important because it shows that some people can have changes in UMPS without having the serious health consequences typically associated with orotic aciduria. Who this helps: This research benefits doctors and patients by improving understanding of genetic variations and their potential effects.

PubMed

Two Novel TEX15 Mutations in a Family with Nonobstructive Azoospermia.

2017

Gynecologic and obstetric investigation

Colombo R, Pontoglio A, Bini M

Plain English
This study looked at a family with two brothers who were infertile due to a condition called nonobstructive azoospermia (NOA), meaning they had no sperm in their semen. Researchers found two specific mutations in a gene called TEX15 that appear to be linked to their infertility. Since TEX15 is important for sperm production, understanding its role helps explain some cases of NOA that don't have clear genetic causes. Who this helps: This helps patients with infertility issues and their doctors in identifying potential genetic causes and treatment options.

PubMed

Caution in interpretation of disease causality for heterozygous loss-of-function variants in the MYH8 gene associated with autosomal dominant disorder.

2017

European journal of medical genetics

Dai Z, Whitt Z, Mighion LC, Pontoglio A, Bean LJH +2 more

Plain English
This study looked at a specific gene change in the MYH8 gene, which has been linked to a condition called trismus-pseudocamptodactyly syndrome. Researchers found that 16 individuals had changes in this gene, but none had the syndrome; four of these individuals had issues explained by changes in other genes. These findings show that changes in the MYH8 gene do not cause the syndrome and stress the need to carefully evaluate genetic data to understand health conditions. Who this helps: This helps doctors and genetic counselors better understand genetic testing results for patients.

PubMed

A STAG3 missense mutation in two sisters with primary ovarian insufficiency.

2017

European journal of obstetrics, gynecology, and reproductive biology

Colombo R, Pontoglio A, Bini M

PubMed

The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing.

2015

Scientific reports

Tesori V, Piscaglia AC, Samengo D, Barba M, Bernardini C +8 more

Plain English
This study looked at how the cancer drug Sorafenib affects liver cancer cells. Researchers found that while Sorafenib alone had a limited effect on killing these cells, it caused damage to their mitochondria and increased harmful molecules that lead to cell death. When the supply of glucose was cut off or when a specific glycolysis blocker was used, the effectiveness of Sorafenib in killing the cancer cells increased significantly, highlighting a potential strategy to overcome resistance to the drug. Who this helps: This research helps cancer patients, especially those with liver cancer, by providing insights for more effective treatment options.

PubMed

Mitochondrial proteomic approaches for new potential diagnostic and prognostic biomarkers in cancer.

2012

Advances in experimental medicine and biology

Bottoni P, Giardina B, Pontoglio A, Scarà S, Scatena R

Plain English
Researchers studied the proteins found in mitochondria, which are tiny energy factories in our cells, to better understand how they relate to cancer. They identified over 1,000 specific mitochondrial proteins and discovered that some of these proteins behave differently in cancer cells compared to normal cells. This is important because it could lead to new ways to diagnose and treat cancer by focusing on these altered proteins. Who this helps: This benefits patients with cancer and their doctors by providing new tools for diagnosis and potential treatments.

PubMed

Cancer stem cells: the development of new cancer therapeutics.

2011

Expert opinion on biological therapy

Scatena R, Bottoni P, Pontoglio A, Giardina B

Plain English
This study looked at cancer stem cells (CSCs), a special group of cells within tumors that can grow indefinitely and are key players in cancer progression. Researchers found that targeting specific proteins and pathways associated with CSCs could lead to new treatments for cancer, and promising early results suggest these therapies may improve diagnosis and treatment methods. This is important because it could provide more effective options for patients faced with difficult-to-treat cancers. Who this helps: This helps cancer patients and doctors looking for better treatment strategies.

PubMed

The proteomics of cancer stem cells: potential clinical applications for innovative research in oncology.

2011

Proteomics. Clinical applications

Scatena R, Bottoni P, Pontoglio A, Giardina B

Plain English
This study focused on cancer stem cells (CSCs), which are special cells in tumors that can make more cancer cells and contribute to tumor growth. Researchers found that certain markers on these cells can help identify them and could be targeted by existing and new cancer treatments. By better understanding CSCs, there is potential for developing more effective therapies that could improve outcomes for cancer patients. Who this helps: This helps patients facing cancer treatment challenges.

PubMed

Pharmacological modulation of nitric oxide release: new pharmacological perspectives, potential benefits and risks.

2010

Current medicinal chemistry

Scatena R, Bottoni P, Pontoglio A, Giardina B

Plain English
This research paper looks at how nitric oxide (NO) works in the body and explores new drugs that can safely increase its release. Researchers found that while existing drugs, like nitrates, can help treat problems related to blood flow and inflammation, they often cause side effects, such as headaches or low blood pressure. By developing new types of drugs that better control NO release, there is potential to treat issues like blood vessel diseases and chronic inflammation more effectively while minimizing risks. Who this helps: This helps patients with circulatory issues, inflammatory diseases, and doctors looking for safer treatment options.

PubMed

Revisiting the Warburg effect in cancer cells with proteomics. The emergence of new approaches to diagnosis, prognosis and therapy.

2010

Proteomics. Clinical applications

Scatena R, Bottoni P, Pontoglio A, Giardina B

Plain English
This study focused on how cancer cells use sugar differently than normal cells, specifically looking at the Warburg effect, which is when cancer cells absorb a lot of glucose for energy. Researchers found that cancer cells display unique patterns in the proteins involved in sugar metabolism, suggesting that they have adapted in complex ways that could change how we diagnose and treat cancer. Understanding these patterns could lead to better tools for identifying and treating cancer effectively. Who this helps: Patients and doctors involved in cancer diagnosis and treatment.

PubMed

Glycolytic enzyme inhibitors in cancer treatment.

2008

Expert opinion on investigational drugs

Scatena R, Bottoni P, Pontoglio A, Mastrototaro L, Giardina B

Plain English
This study explores how certain drugs that block glycolysis, a process cancer cells rely on for energy, can improve cancer treatment. Researchers found that these glycolytic enzyme inhibitors can enhance the effectiveness of other cancer therapies by targeting the unique energy needs of cancer cells, potentially making treatments more selective and reducing resistance. This matters because it could lead to better outcomes for patients by using existing treatments more effectively and overcoming challenges like drug resistance. Who this helps: Cancer patients undergoing treatment.

PubMed

The human muscle proteome in aging.

2006

Journal of proteome research

Gelfi C, Vigano A, Ripamonti M, Pontoglio A, Begum S +5 more

Plain English
This study looked at how the proteins in a specific muscle (the vastus lateralis) change as people get older, comparing physically active elderly adults to younger individuals. The researchers found that older adults had fewer regulatory proteins needed for muscle contraction and different types of myosin proteins, which indicates a shift in how their muscles use energy. This matters because understanding these changes can help us find ways to maintain muscle function in older people. Who this helps: This helps elderly patients and healthcare providers working on muscle health.

PubMed

Peptide and protein separations by capillary electrophoresis in the presence of mono- and diquaternarized diamines.

2004

Electrophoresis

Pontoglio A, Viganò A, Sebastiano R, Citterio A, Maragnoli L +2 more

Plain English
This study looked at two specific compounds to see how they affect the separation of peptides and proteins during a lab technique called capillary zone electrophoresis. The researchers found that one compound, M7C4I, provided clear separation of peptides in low pH conditions, while the other compound, C10M7C10, worked better for smaller chains of amino acids but wasn't as effective for larger proteins. These findings matter because they can improve how scientists analyze different proteins, which is important for understanding diseases and developing treatments. Who this helps: This helps researchers and scientists working on drug development and disease diagnosis.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.